Antibiotikaresistens hos stammar av Helicobacter pylori i Göteborg: Bakterierna resistenta mot metronidazol

Lakartidningen

Volumn , Issue 4, 1998, Pages 279-281

  Jaup, Bernhard H ^a,e   Brandberg, Åke ^b   Stenquist, Bo ^c   Norrby, Anders ^a,d  

^a Södra Älvsborgs Sjukhus   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c Kirurgkliniken   (Sweden)

^d Samtliga Göteborg   (Sweden)

^e Lundby Sjukhus   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITRICHOMONAL AGENT; METRONIDAZOLE;

ARTICLE; DRUG EFFECT; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; IMMUNOLOGY; MALE; MULTIDRUG RESISTANCE; SWEDEN;

ANTITRICHOMONAL AGENTS; DRUG RESISTANCE, MULTIPLE; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; SWEDEN;

EID: 0032553968     PISSN: 00237205     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Coghlan JG, Gilligan D, Humphries H, McKenna D, Dooley C, Sweeney E et al. Campylobacter pylori and recurrence of duodenal ulcers - a 12-month follow-up study. Lancet 1987; 2: 1109-11.
2. Forman D. Helicobacter pylori and gastric cancer. Scand J Gastroenterol 1996; 31 suppl 215: 48-51.
3. Bayerdörffer E, Morgner A, Neubauer A, Rudolph B, Thiede C, Lehn N et al. Regression of primary gastric MALT lymphoma after cure of H pylori infection: A two-year follow-up report of the German MALT lymphoma trial. Gastroenterology 1996; 110: 490A.
4. Lee J, O'Morain C. Consensus or confusion: a review of existing national guidelines on Helicobacter pylori-related disease. Eur J Gastroenterol Hepatol 1997; 9: 527-31.
5. Glupczynski Y. Susceptibility of a multicentre European survey in 1991 of metronidazole resistance in H pylori. Eur J Clin Microbiol Infect Dis 1992; 11: 777-81.
6. Nya råd från Läkemedelsverket: Trippelregim krävs mot H pylori. Läkartidningen 1996; 11: 1041-5.
7. Glupczynski Y, Goutier S, Van den Borre C, Butzler JP, Burette A. Surveillance of H pylori resistance to antimicrobial agents in Belgium from 1989 to 1994. Gut 1995; 37 suppl 1: 56A.
8. Reddy R, Osato M, Gutiérrez O, Kim JG, Graham DY. Metronidaloze resistance is high in Korea and Columbia and appears to be rapidly increasing in the US. Gastroenterology 1996; 110: 238A.
9. Cayla R, Zerbib F, Mégraud F, Lamouliatte H. Clarithromycin resistance of Helicobacter pylori strains before and after treatment: A key factor of treatment failures. Gastroenterology 1995; 108: 68A.
10. Midolo PD, Lambert JR, Turnbridge J. Metronidazole resistance: A predictor of failure of H pylori eradication by triple therapy. J Gastroenterol Hepatol 1996; 11: 290-2.
11. Bazzoli F, Zagari RM, Fossi S, Pozzato P, Alampi G, Sottili S. Efficacy and tolerability of a short-term, low-dose triple therapy for eradication of H pylori. Gastroenterology 1993; 104: 140A.
12. Jaup BH, Norrby A. Low dose, short term triple therapy for cure of H pylori infection and healing of peptic ulcers. Am J Gastroenterol 1995; 90: 943-5.
13. Moayyedi P, Sahay P, Tompkins DS, Axon ATR. Efficacy and optimum dose of omeprazole in a new 1-week triple therapy regimen to eradicate H pylori. Eur J Gastroenterol Hepatol 1995; 7: 835-40.
14. Buckley M, Keating S, Xia H, Beattis S, Hamilton H, O'Morain C. Omeprazole plus one or two antibiotics to eradicate H pylori. Gastroenterology 1995; 108: 63A.
15. Jaup BH, Norrby A. Comparison of two low-dose one-week triple therapy regimens with and without metronidazole for cure of H pylori infection. Aliment Pharmacol Ther 1996; 10: 275-7.
16. Peitz U, Nusch A, Tillenburg B, Becker T, Stolte M, Börsch G et al. Frequent metronidazole resistance without significant impact on the high cure rate of H pylori by triple therapy with omeprazole, metronidazole and clarithromycin. Gastroenterology 1996; 110: 226A.